LL/2: An Immunosuppressive Murine Tumor Model

Lung cancer is the second most common cancer diagnosed in both men and women in the United States and is, by far, the most common cause of cancer-related deaths in men and women. In 2019, the American Cancer Society estimates that 228,150 new cases of lung cancer (116,440 in men and 111,710 in women) will […]

PyMT – A Transplantable Murine Model of Breast Cancer

Breast cancer remains one of the most prolific and life-threatening diseases among women worldwide. According to the American Cancer Society, among US women in 2017, there were approximately 253,000 new cases of invasive breast cancer resulting in 41,000 deaths.[1] Approximately 6-10% of new breast cancer cases (15,000-25,000) are diagnosed as metastatic (Stage IV). However, it […]

A Deeper Dive into the Tumor-Infiltrating T Cell Immunophenotype

A Deeper Dive into the Tumor-Infiltrating T Cell Immunophenotype – Introducing the New MI-Expanded CompT™ Multi-Color Flow Cytometry Panel Flow cytometry using large antibody panels has the advantage of examining a greater number of cell subsets. This capability is particularly important when a comprehensive data set is required, but limited […]

Pan02: A Murine Model of Pancreatic Cancer

Pancreatic cancer is the ninth most commonly diagnosed cancer and ranks as one of the deadliest with the lowest 5-year survival rate of 5-8%.[1,2,3] This year alone, the American Cancer Society estimates that 56,770 people will be diagnosed with the disease of which more than 45,750 people may not survive. Pancreatic ductal adenocarcinoma (PDAC) being […]

MB49 – A Bladder Cancer Murine Tumor Model

Bladder cancer is one of the most frequent cancers of the urinary tract, accounting for about 80,000 new cases and 18,000 deaths in the United States in 2018, according to the National Cancer Society. Typically, patients with bladder cancer have limited surgical or treatment options. Traditional chemotherapeutics are ineffective, and surgery is often used to […]

TIGIT Directed Human Antibody Modulates T-regulatory and Effector Cell Function

MI Bioresearch was mentioned within in the Seattle Genentics poster they presented at the AACR 2019 Conference. Stated under the “SGN-TIGIT displays strong anti-tumor efficacy” figures: “SGN-TIGIT treatment in CT26 and A20 syngeneic models cured 50% and 33% of animals, respectively. SGN-TIGIT in the MC38, E0771, EMT6, and an alternative […]

Radiation Response in Preclinical Orthotopic Models of Brain Cancer

Introduction and Background Glioblastoma multiforme (GBM) is a fast-growing, aggressive type of central nervous system tumor that forms on the supportive tissue of the brain. It is the most common primary brain tumor. The American Cancer Society estimates that in 2019 there will be >23,000 new cases diagnosed and >17,000 […]

Comprehensive Dendritic Cell Analysis by Flow Cytometry Using the New MI-CompDC™ Panel

Table 1: MI-CompDC™ Panel Antibodies and Description of Their Utility Antibody/Dye Description CD45 Pan immune cell marker F4/80, Ly-6G, CD19 Exclusion gate for macrophages, granulocytes, and B cells CD11c Dendritic cell marker CD24 Dendritic cell marker CD8 DC1 marker MHC Class II Dendritic cell marker/maturation marker CD103 DC1 marker CD11b […]

Combined Focal Radiation and Anti-mCTLA-4 Antibody Therapy Modulates Myeloid Subset Phospho-STAT3 Levels in the 4T1 Tumor Microenvironment, and Results in Tumor Growth Inhibition

Introduction and Background Signaling through signal transducer and activator of transcription factor 3 (STAT3) in myeloid subsets triggers gene expression that has direct and indirect suppressive effects on several immune subsets. Selective targeting of STAT3 in myeloid cells has become an attractive therapeutic approach as it can prevent adverse effects […]

An Introduction to Dendritic Cell Biology and Analysis Using Syngeneic Immuno-Oncology Models

Productive immunotherapy driven anti-tumor responses rely on the activation of T cells that target tumor-associated antigens (TAA). The dendritic cell (DC) plays an essential role in the activation of T cell antigen-specific responses, which occurs naturally in the context of infection. However, this same process supports tumor immune surveillance as well as active anti-tumor responses. […]

E0771 Syngeneic Breast Cancer Model

Triple negative breast cancer (TNBC) is a complex and aggressive subtype of breast cancer lacking estrogen receptor, progesterone receptor, and HER2 amplifications; making it difficult to target therapeutically. Consequently, there’s a constant demand for better treatment options for TNBC. To help address the need for TNBC models, we highlighted the EMT6 model last month and […]

Flow Cytometry-Based Tools to Enrich Your Preclinical Immuno-Oncology Research

Overview: Flow cytometry provides a highly adaptable and quantitative method for investigating both the cellular distribution and intracellular changes that occur in tumors and peripheral lymphoid organs in response to therapy. As clinical successes with cancer immunotherapy accumulate, preclinical immuno-oncology research depends on greater mechanistic understanding of novel therapeutic strategies. […]

High-Throughput Analysis of MAPK and JAK-STAT Signaling in CT26 Tumors Using a Combination of Immunophenotyping and Phospho-Flow Cytometry

Introduction and Background The development of robust platforms that enable phospho-protein-based analysis of cell signaling in the tumor microenvironment is pivotal for small molecule drug development. Currently lacking are reliable applications that can simultaneously measure multiple phospho-proteins in both tumor cells and immune cells ex vivo. This can be crucial […]

Phospho-Protein Detection in Solid Tumors Using Phospho-Flow Cytometry

About the Author: Dr. David Draper is an immunologist and senior member of the Flow Cytometry Team at MI Bioresearch since 2015. Dr. Draper holds a Ph.D. in Microbiology from North Carolina State University. His post-doctoral work at Duke University and the National Institutes of Health focused on uncovering the […]

Phospho-Flow Cytometry for the Screening of Intracellular Signaling Events in Cancer Cells and Immune Cells

Pre-clinical research on the development of small molecule inhibitors that block the activity of disease-associated kinases continues to be a major focus of cancer therapy. Therefore, robust platforms that can quantify the phosphorylation state of these kinases are valuable to drug development efforts. Using the MV-4-11 acute myeloid leukemia (AML) model, this update describes new […]

Characterization of Proliferation in Multiple Lymphocyte Subsets in the CT26 Murine Colon Carcinoma Model by Multi-color Flow Cytometry

“Characterization of Proliferation in Multiple Lymphocyte Subsets in the CT26 Murine Colon Carcinoma Model by Multi-color Flow Cytometry” Introduction and Background: The efficacy of immune-modulating anti-cancer therapeutic antibodies that have been FDA-approved in recent years, such as anti-CTLA-4, anti-PD-1, and anti-PD-L1, has altered the paradigm of cancer treatment. Subsequently, the […]

C1498: A Murine Model for Acute Myelogenous Leukemia (AML)

Survival (morbidity/mortality) kinetics (Figure 2A) show a median survival of approximately 23 days; although, the mice show no body weight loss during the course of disease progression (Figure 2B). Survival Kinetics and Body Weight Change Fig. 2: Survival kinetics (A) and body weight change (B) of C57BL/6 mice with disseminated […]